Healthcare Sales & Marketing Network News: bisphosphonate

Searching News Database: bisphosphonate

HSMN NewsFeed - 29 May 2023
Abiogen Pharma Completes the Acquisition of Effrx
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 14 Jul 2022
Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion's MAFTEST(R) reduces the risk of death in comparison with current clinical guidance
Diagnostics Oncology

HSMN NewsFeed - 12 Dec 2019
European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 18 Oct 2019
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Biopharmaceuticals Regulatory

HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 16 Dec 2016
Grünenthal Receives Breakthrough Therapy Designation From U.S. FDA for Neridronic Acid for the Treatment of CRPS
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Aug 2013
Hologic Launches New Bone Densitometer Platform for Osteoporosis, Cardiovascular Disease, and Obesity Assessment
Devices Radiology Product Launch

HSMN NewsFeed - 10 May 2013
Novartis drug Ilaris(R) approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Biopharmaceuticals. FDA

HSMN NewsFeed - 11 Oct 2010
Warner Chilcott Announces FDA Approval of Next Generation Actonel
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jun 2010
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA

HSMN NewsFeed - 16 Dec 2009
Merck Appoints Dr. Michael Rosenblatt As Executive Vice President & Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Dec 2009
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Sep 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Dec 2008
New Data Shows Zometa(R) Enhances Impact of Chemotherapy on Reducing Breast Tumour Size
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Dec 2008
First Head-To-Head Study Shows That Protelos(R) (Strontium Ranelate) Builds Better Bone Than Bisphosphonate
Biopharmaceuticals

HSMN NewsFeed - 23 Sep 2008
Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Sep 2008
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
Biopharmaceuticals

HSMN NewsFeed - 31 May 2008
Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Premenopausal Women With Early-Stage Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Mar 2008
Samaritan Pharmaceuticals Acquires Commercialization Rights to Market and Distribute Abiogen's Cancer Drug Abioklad in Greece, Cyprus and Turkey
Biopharmaceuticals Distribution

HSMN NewsFeed - 28 Feb 2008
Procter & Gamble Wins Patent Infringement Lawsuit for Osteoporosis Therapy Actonel
Biopharmaceuticals Litigation

HSMN NewsFeed - 15 Dec 2007
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Sep 2007
New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
Biopharmaceuticals

HSMN NewsFeed - 18 Sep 2007
Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
Biopharmaceuticals

HSMN NewsFeed - 18 Sep 2007
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Biopharmaceuticals

HSMN NewsFeed - 18 Aug 2007
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Aug 2007
Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 4 Jun 2007
Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 May 2007
Once-yearly Reclast(R) Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
Biopharmaceuticals Orthopaedic

HSMN NewsFeed - 24 Apr 2007
Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
Biopharmaceuticals FDA

HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Feb 2007
BioMimetic Therapeutics Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteonecrosis of the Jaw
Biopharmaceuticals FDA

HSMN NewsFeed - 29 Jan 2007
NCCN Updates Prostate Cancer Guidelines
Devices Surgery Oncology

HSMN NewsFeed - 28 Sep 2006
Sciele Pharma Introduces OSTIVA(TM), a New Women's Health Product
Biopharmaceuticals

HSMN NewsFeed - 19 Sep 2006
Higher Persistency Rates Seen with FOSAMAX(R) Once Weekly Therapies Compared to Other Weekly and Monthly Oral Bisphosphonates, According to Two New Outcomes Studies
Biopharmaceuticals

HSMN NewsFeed - 17 Sep 2006
Women More Likely to Stay on Once-Monthly Boniva(R) Versus Once-Weekly Osteoporosis Medicines
Biopharmaceuticals

HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals

HSMN NewsFeed - 12 Sep 2006
Chugai Announces Co-Development and Co-Marketing Agreement with Taisho Pharmaceutical for the Antiresorptive Bisphosphonate R484
Biopharmaceuticals Licensing

HSMN NewsFeed - 31 May 2006
First North American Patient Undergoes MR Guided Focused Ultrasound Surgery to Ease Pain From Bone Metastases
Devices Surgery

Return to NewsFeed

Additional items found! 45

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 45 additional stories matching:
bisphosphonate
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.